The Cancer Genome Atlas Pan-Cancer Analysis Project
By John N. Weinstein, E. Collisson, Gordon B. Mills, K. Shaw, B. Ozenberger, K. Ellrott, Ilya Shmulevich, Christopher Sander, Joshua M. Stuart. 2013
8,331 citations recorded by the source corpus.
Current clinical practice is organized according to tissue or organ of origin of tumors. Now, The Cancer Genome Atlas (TCGA) Research Network has started to identify genomic and other molecular commonalities among a dozen different types of cancer. Emerging similarities and contrasts will form the basis for targeted therapies of the future and for repurposing existing therapies by molecular rather than histological similarities of the diseases. The Cancer Genome Atlas (TCGA) Research Network has profiled and analyzed large numbers of human tumors to discover molecular aberrations at the DNA, RNA, protein and epigenetic levels. The resulting rich data provide a major opportunity to develop an integrated picture of commonalities, differences and emergent themes across tumor lineages. The Pan-Cancer initiative compares the first 12 tumor types profiled by TCGA. Analysis of the molecular aberrations and their functional roles across tumor types will teach us how to extend therapies effective in one cancer type to others with a similar genomic profile.
Subfields: Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Michael I. Love
- Rob Patro
- Casey S. Greene
- G. Way
- Maria D. Paraskevopoulou
- Theodore Dalamagas
- Ioannis S. Vlachos
- Thanasis Vergoulis
In Pathology and Forensic Medicine
- Angel Cruz-Roa
- Natalie N. C. Shih
- Fabio A. González
- Peter W. Laird
- Anant Madabhushi
- Hannah Gilmore
- John Tomaszewski
- Ajay Basavanhally
In Pulmonary and Respiratory Medicine
Citations in the corpus
- WILDS: A Benchmark of in-the-Wild Distribution Shifts (2020, neutral): “…leading to potential subpopulation shift issues, e.g,. a rare cancer subtype in one context might be more common in another; or even if it remains rare, we would seek to leverage the greater quantity of data from other subtypes to improve model accuracy on the rare subtype (Weinstein et al., 2013).”
- A foundation model for clinical-grade computational pathology and rare cancers detection (2024, neutral): “https://doi.org/10.1038/s41591-024-03141-0 datasets—orders of magnitude greater than any used historically for computational pathology—using a family of algorithms, referred to as self-supervised learning (for example, refs.”
- The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery (2015, methodology): “Historically, most genetic and genomic data sharing has been accomplished through the aggregation of data in a single “centralized” site, such as the National Center for Biotechnology Information’s (NCBI) Database of Genotypes and Phenotypes (dbGaP) [Tryka et al., 2013] or other large data centers s”
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020, neutral): “…genomic revolution in cancer has led to the identification and pursuit of numerous genetic drivers of malignancy (The Cancer Genome Atlas Research Network et al., 2013; The International Cancer Genome Consortium, 2010), but these efforts have relied, by necessity, on bulk profiling of advanced…”
- Federated learning for medical image analysis: A survey (2023, background): “3) Histology: TCGA: The Cancer Genome Atlas (TCGA) [145] 17 is a large-scale landmark cancer genomics database.”
- A pathology atlas of the human cancer transcriptome (2017, neutral): “The database resource from TCGA represents a comprehensive and coordinated effort to accelerate our understanding of cancer (5), and the HPA and GTEx represent international efforts to map the expression of protein-coding genes in normal human tissues.”
- DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions (2017, methodology): “It provides information regarding the miRNA, the targeted gene and the binding site location, while its sixth version has been enhanced with miRNA/mRNA profiles retrieved from the Cancer Genome Atlas (12).”
- Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference (2017, methodology): “These estimates are used for the classification of diseases and their subtypes [1], for understanding expression changes during development [2], and tracking the progression of cancer [3].”